SUMO-specific protease 2 in Mdm2-mediated regulation of p53

Genetic analysis in mice has revealed a key genetic pathway, SUMO-specific protease 2 (SENP2)-Mdm2-p53, essential for trophoblast development. Targeted disruption of SENP2 impairs the G–S transition required for mitotic and endoreduplication cell cycles during the expansion of trophoblast stem cells and their differentiation into polyploidy cells, respectively. The disruption disturbed the subcellular distribution and SUMO modification of Mdm2, leading to interference with p53 degradation. Here, we further explore the mechanism underlying SENP2-mediated regulation of Mdm2 in p53-induced cellular stress. We identify a specific isoform of SENP2 necessary and sufficient to negatively regulate the p53-dependent transcription and its related stress responses. This isoform-specific effect is attributed to the differential compartmentalization of SENP2. SUMO conjugation of Mdm2 induces its co-localization and association with SENP2 in promyelocytic leukemia bodies. Biochemical studies show that SENP2 catalyzes the desumoylation process of Mdm2. SENP2-dependent regulation of Mdm2 is sensitive to its p53-binding activity. Our findings led us to propose a mechanism underlying the SENP2-mediated regulation of Mdm2 that is critical for genome integrity in p53-dependent stress responses.

[1]  L. Hengst,et al.  SUMO-1 and p53 , 2002, Cell cycle.

[2]  S. Jackson,et al.  Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks , 2009, Nature.

[3]  K. Kinzler,et al.  Genetic determinants of p53-induced apoptosis and growth arrest. , 1996, Genes & development.

[4]  M. Tatham,et al.  Polymeric Chains of SUMO-2 and SUMO-3 Are Conjugated to Protein Substrates by SAE1/SAE2 and Ubc9* , 2001, The Journal of Biological Chemistry.

[5]  T. Jacks,et al.  Characterization of the p53-Dependent Postmitotic Checkpoint following Spindle Disruption , 1998, Molecular and Cellular Biology.

[6]  Melanie Keppler,et al.  The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress , 2009, Nature.

[7]  K. Shuai,et al.  Resolution of Sister Centromeres Requires RanBP2-Mediated SUMOylation of Topoisomerase IIα , 2008, Cell.

[8]  R. Margolis,et al.  Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. , 2001, Molecular biology of the cell.

[9]  W. Hsu,et al.  Expression of Gpr177, a Wnt trafficking regulator, in mouse embryogenesis , 2010, Developmental dynamics : an official publication of the American Association of Anatomists.

[10]  J. Marine.  p53 stabilization: the importance of nuclear import , 2010, Cell Death and Differentiation.

[11]  R. Hay,et al.  SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. , 1998, Molecular cell.

[12]  F. Melchior,et al.  SUMO--nonclassical ubiquitin. , 2000, Annual review of cell and developmental biology.

[13]  A. Dejean,et al.  Nuclear and unclear functions of SUMO , 2003, Nature Reviews Molecular Cell Biology.

[14]  Wei Gu,et al.  Modes of p53 Regulation , 2009, Cell.

[15]  J. Marine,et al.  Mdm2-mediated ubiquitylation: p53 and beyond , 2010, Cell Death and Differentiation.

[16]  Wei Hsu,et al.  SUMO-Specific Protease 2 Is Essential for Modulating p53-Mdm2 in Development of Trophoblast Stem Cell Niches and Lineages , 2008, PLoS biology.

[17]  S. Müller,et al.  SUMO: a regulator of gene expression and genome integrity , 2004, Oncogene.

[18]  D. Green,et al.  Cytoplasmic functions of the tumour suppressor p53 , 2009, Nature.

[19]  David C Schwartz,et al.  A superfamily of protein tags: ubiquitin, SUMO and related modifiers. , 2003, Trends in biochemical sciences.

[20]  C. Deng,et al.  The Balance of WNT and FGF Signaling Influences Mesenchymal Stem Cell Fate During Skeletal Development , 2010, Science Signaling.

[21]  Alexei Vazquez,et al.  The genetics of the p53 pathway, apoptosis and cancer therapy , 2008, Nature Reviews Drug Discovery.

[22]  Karen H. Vousden,et al.  p53 in health and disease , 2007, Nature Reviews Molecular Cell Biology.

[23]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[24]  F. Melchior,et al.  SUMO: ligases, isopeptidases and nuclear pores. , 2003, Trends in biochemical sciences.

[25]  Jiaoti Huang,et al.  Co-opted JNK/SAPK Signaling in Wnt/β-catenin-Induced Tumorigenesis , 2008 .

[26]  D. Pellman,et al.  From polyploidy to aneuploidy, genome instability and cancer , 2004, Nature Reviews Molecular Cell Biology.

[27]  J. Fraumeni,et al.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? , 1969, Annals of internal medicine.

[28]  Pier Paolo Pandolfi,et al.  PML regulates p53 acetylation and premature senescence induced by oncogenic Ras , 2000, Nature.

[29]  W. Hsu,et al.  Reciprocal regulation of Wnt and Gpr177/mouse Wntless is required for embryonic axis formation , 2009, Proceedings of the National Academy of Sciences.

[30]  W. Hsu,et al.  Craniosynostosis caused by Axin2 deficiency is mediated through distinct functions of beta-catenin in proliferation and differentiation. , 2007, Developmental biology.

[31]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[32]  J. Palvimo,et al.  SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells. , 2009, Molecular endocrinology.

[33]  P. Pandolfi,et al.  Regulation of p53 activity in nuclear bodies by a specific PML isoform , 2000, The EMBO journal.

[34]  G. Gill,et al.  SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? , 2004, Genes & development.

[35]  I. Roninson,et al.  Repression of the SUMO‐specific protease Senp1 induces p53‐dependent premature senescence in normal human fibroblasts , 2008, Aging cell.

[36]  Eduardo Sontag,et al.  Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.

[37]  F. Costantini,et al.  Impaired neural development caused by inducible expression of Axin in transgenic mice , 2007, Mechanisms of Development.

[38]  A. Levine,et al.  The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.

[39]  W. Birchmeier,et al.  The role of Axin2 in calvarial morphogenesis and craniosynostosis , 2005, Development.

[40]  D. Meek.  Tumour suppression by p53: a role for the DNA damage response? , 2009, Nature Reviews Cancer.

[41]  U. Knippschild,et al.  Posttranslational modification of MDM2. , 2003, Molecular cancer research : MCR.